Novo Nordisk IT unit set to announce IPO; Alexion weighs new European HQ in Zurich;

@FiercePharma: Our newest special report is live! The top 10 most expensive drugs of 2013. Feature | Follow @FiercePharma

@EricPFierce: Novartis says construction delay of Russian plant no big deal, technical changes and not tied to sanctions. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Sanofi wins kudos for airing bribery probe. Phase II? Take to social media. Article | Follow @CarlyHFierce

> Novo Nordisk ($NVO) is on the brink of announcing an initial public offering for its information technology unit, NNIT, a Danish newspaper reports; the drugmaker said in January that it was considering an NNIT spinoff. Report

> U.S.-based Alexion Pharmaceuticals ($ALXN) says it's weighing a move of its European headquarters to Zurich, as part of a plan to expand operations in the country. Report

> The Belgian biotech Galapagos wooed its new chief financial officer, Bart Filius, away from his post as VP of Sanofi Europe. Report

> AstraZeneca's ($AZN) new head of investor relations says he's looking to set up an IR beachfront in the U.S. Report

> Retrophin ($RTRX) agreed to sell off some "non-core" assets, including the oxytocin nasal spray Syntocinon, to Turing Pharmaceuticals for $3 million, plus debt assumption. Release

Medical Device News

@FierceMedDev: Who are today's leading women in med tech? Check out our top women in medical devices list to find out. Special report | Follow @FierceMedDev

@VarunSaxena2: Invitae raises $120M to offer cheap, easy genetic analysis. Story | Follow @VarunSaxena2

@EmilyWFierce: $COV recalled some defibrillator electrodes made by $PHG. Story from MassDevice | Follow @EmilyWFierce

@MichaelGFierce: Stem cell-derived beta cells deliver insulin in response to blood sugar levels. Story | Follow @MichaelGFierce

> In latest M&A news, ConvaTec is up for sale. Story

> St. Jude posts modest gains in Q3 financials led by new products. Article

> Beyond glucose: Developing a diagnostic test for fructose intolerance. More

Biotech News

@FierceBiotech: Meet some of the revolutionaries in biotech R&D. Report | Follow @FierceBiotech

@JohnCFierce: AbbVie to Shire: Maybe we should reconsider that $54B merger deal after all - $SHPG down 27%. Article | Follow @JohnCFierce

@DamianFierce: Fantastically timed press release: "Shire Announces the Organize Your Stuff Contest Winners." Release | Follow @DamianFierce

@EmilyMFierce: These 10 drugs could stop Ebola. Feature | Follow @EmilyMFierce

> Selecta banks $20M for trial work, inks a pact with Sanofi on diabetes. Story

> Forward Pharma pulls off a $221M IPO with eyes on unseating Biogen. More

> DNAtrix pockets $20M to get its cancer-fighting virus into Phase III. Article

Drug Delivery News

> Robert Langer talks science, business and how they intersect. More

> Stem cell-derived beta cells deliver insulin in response to blood sugar levels. Story

> Stealthy, DNA-based 'nano-cocoons' deliver cancer-killing payloads. Report

> Alnylam releases data on its Phase II study of TTR-mediated amyloidosis patients. Item

> Intersect ENT says latest data on dissolving implants for chronic sinusitis are encouraging. Article

Diagnostics News

> Gene sequencing helps Northwestern team diagnose one cause of epilepsy. More

> Exact Sciences nails coveted Medicare coverage for colon cancer DNA test. News

> SomaLogic, CO hospital to develop biomarkers/Dx tests for childhood diseases. Story

> British startup finishes quick and easy Ebola test. Report

> Biocept, Rosetta Genomics want to beef up Dx and biomarker-detection power. Article

Pharma Marketing News

> Teva's SCOTUS appeal is here. But how much can the outcome really affect Copaxone's market share? More

> World's best CEOs? Gilead, Allergan, Novo and Valeant make top 10. Read

> Looking 'beyond the pill'? Start with an app--and then follow this to-do list. Story

> Can Amgen's marketing muscle vault its Humira biosim ahead of rivals? More

> Pictures tell the story in AstraZeneca's breast cancer photo-sharing push. Article

And Finally... How a cooling cap could change breast cancer treatment. Report

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.